亿帆医药(002019) - 2019 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥256,717,586.18, representing a 49.75% increase year-on-year[2]. - Operating revenue for the period was ¥1,278,249,704.18, up 15.36% from the same period last year[2]. - Basic earnings per share were ¥0.21, reflecting a 50.00% increase compared to the previous year[2]. - The company reported a non-recurring profit of ¥98,949,416.72 for the period[3]. - Total revenue for Q3 2019 reached ¥1,278,249,704.18, an increase of approximately 15.4% compared to ¥1,108,091,639.36 in the same period last year[29]. - Operating profit for Q3 2019 was ¥294,562,763.82, up from ¥199,196,872.03 in Q3 2018, reflecting a growth of about 47.8%[30]. - Net profit attributable to the parent company for Q3 2019 was ¥256,717,586.18, compared to ¥171,426,622.79 in Q3 2018, representing a year-over-year increase of approximately 49.8%[30]. - The company reported a total profit of ¥882,362,706.34, compared to ¥847,611,026.59 in the previous year, reflecting a growth of 4.1%[37]. Assets and Liabilities - Total assets at the end of the period reached ¥10,356,003,365.49, an increase of 5.95% compared to the previous year[2]. - The total number of shareholders at the end of the period was 53,605, with the top ten shareholders holding 42.34% of the shares[4]. - The total liabilities decreased slightly to ¥2.69 billion from ¥2.89 billion, a reduction of approximately 6.9%[23]. - The company's equity attributable to shareholders increased to ¥7.28 billion from ¥6.62 billion, representing a growth of about 9.9%[24]. - Total assets as of September 30, 2019, amounted to ¥7,114,141,620.23, an increase from ¥6,173,057,573.39 at the end of 2018, indicating a growth of about 15.2%[28]. - Total liabilities decreased to ¥1,033,570,819.85 in Q3 2019 from ¥1,261,750,791.64 in Q3 2018, a reduction of approximately 18.0%[27]. - Total liabilities were reported at ¥2,887,212,314.92, with current liabilities at ¥2,396,235,525.19[49]. Cash Flow - Net cash flow from operating activities was ¥269,951,155.72, a decrease of 58.14% year-to-date[2]. - The company’s cash flow from financing activities showed a net outflow of RMB 140,985,599.61, a decrease of 46.49% compared to RMB -263,461,714.84 in the previous year[11]. - Cash flow from operating activities showed a net outflow of CNY 67,132,082.11, contrasting with a net inflow of CNY 24,609,806.51 in the previous year[45]. - Net cash outflow from operating activities was CNY 381,471,810.77, down from CNY 911,258,835.82 year-over-year[42]. - Net cash outflow from financing activities was CNY 140,985,599.61, improving from CNY 263,461,714.84 in the previous period[43]. Investments and Expenses - The company plans to acquire 100% equity of Perfect Trend Ventures Ltd and Dongren Singapore Pte Ltd for a total cash consideration of RMB 71,630.00 million, which will indirectly result in a 31.65% stake in Bioton S.A.[12]. - The company reported a significant increase in other income, which rose by 1801.02% to RMB 83,425,433.21 from RMB 4,388,445.57, primarily due to increased government subsidies related to operations[11]. - The company reported a decrease in undistributed profits to CNY 510,851,531.58 from CNY 883,046,434.19, a drop of CNY 372,194,902.61[54]. - The company reported a total equity of ¥6,080,570,800.38 as of September 30, 2019, compared to ¥4,911,306,781.75 at the end of 2018, representing an increase of approximately 23.8%[28]. - The company reported investment income of ¥252,617,756.65 for the quarter, a notable increase from ¥4,403,945.00 in the same period last year[33]. Shareholder Information - The largest shareholder, Cheng Xianfeng, holds 42.34% of the shares, amounting to 521,196,307 shares[4]. - The company has no overdue commitments from controlling shareholders or related parties during this period[18]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[18]. Research and Development - Research and development expenses for Q3 2019 were ¥62,789,189.62, significantly higher than ¥34,324,656.94 in Q3 2018, reflecting an increase of about 83.3%[29]. - Research and development expenses surged to ¥17,365,565.67 from ¥200,000.00, marking a significant increase of 8,618.3%[40].